title: Effects of selective COX-2 inhibitors on the gastric permeability of sucrose: a controlled study with placebo and ibuprofen.
abstract: OBJECTIVE
  Acute and chronic use of non-steroidal anti-inflammatory drugs can increase gastrointestinal permeability. Celecoxib, which selectively inhibits the enzyme cyclooxygenase-2, is a novel anti-inflammatory drug with minimal gastrointestinal toxic effects while retaining anti-inflammatory efficacy. Our aim was to assess the potential effects of celecoxib on gastric permeability in comparison with placebo and ibuprofen.
  
  
  METHODS
  We conducted a prospective, double-blind, cross-over study.
  
  
  METHODS
  This study is carried out at Marmara University Hospital.
  
  
  METHODS
  Twenty-five healthy subjects entered the study but 19 subjects completed the treatment.
  
  
  METHODS
  Subjects were randomized to celecoxib 100 mg twice daily, ibuprofen 600 mg twice daily or placebo for 7 days in pre-defined sequences. Treatments were separated by a 7 day washout period.
  
  
  METHODS
  Gastric permeability was assessed by measuring urinary excretion of sucrose spectrophotometrically.
  
  
  RESULTS
  Ibuprofen 600 mg twice daily produced greater increases in gastric permeability compared with placebo or celecoxib (geometric mean of urinary sucrose recovery was 59.15, 32.65 and 33.11 mg/h for ibuprofen, placebo and celecoxib, respectively) (P < 0.001). Celecoxib was generally better tolerated than ibuprofen.
  
  
  CONCLUSIONS
  When compared with ibuprofen, celecoxib 100 mg twice daily has no significant effect on gastric mucosa in healthy subjects.
authors.affiliation: Department of Internal Medicine, Marmara University Faculty of Medicine, Istanbul, Turkey.
authors.forename: Meltem
authors.initials: M
authors.lastname: Ekenel
authors.forename: Erol
authors.initials: E
authors.lastname: Avşar
authors.forename: Neşe
authors.initials: N
authors.lastname: Imeryüz
authors.forename: Meral
authors.initials: M
authors.lastname: Yüksel
authors.forename: Goncagül
authors.initials: G
authors.lastname: Haklar
authors.forename: Ozan
authors.initials: O
authors.lastname: Kocakaya
authors.forename: Nurdan
authors.initials: N
authors.lastname: Tözün
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000494:pharmacology*; D000068579:Celecoxib; D051546:Cyclooxygenase 2; D004311:Double-Blind Method; D005753:Gastric Mucosa / Q000378:metabolism; D006801:Humans; D007052:Ibuprofen / Q000009:adverse effects / Q000494:pharmacology; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D008297:Male; D008565:Membrane Proteins; D010539:Permeability; D011446:Prospective Studies; D011451:Prostaglandin-Endoperoxide Synthases; D011720:Pyrazoles; D013270:Stomach / Q000187:drug effects*; D013395:Sucrose / Q000493:pharmacokinetics* / Q000652:urine; D013449:Sulfonamides / Q000009:adverse effects / Q000494:pharmacology*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D007527:Isoenzymes; D008565:Membrane Proteins; D011720:Pyrazoles; D013449:Sulfonamides; D013395:Sucrose; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D000068579:Celecoxib; D007052:Ibuprofen